RCLL Financials Monday, July 14, 2014 12:26:45 PM
Post# of 4
Posted On: 07/15/2014 12:26:47 AM
RCLL Financials Monday, July 14, 2014 12:26:45 PM
RegenoCell Therapeutics, Inc.
Period Ending Dec 31, 2011 Dec 31, 2010
Total Revenue 865 910
Cost of Revenue 127 92
Gross Profit 738 818
Operating Expenses
Research and Development - -
Sales, General and Admin. 1,537 1,573
Non-Recurring Items - 2,741
Other 64 59
Operating Income (863) (3,555)
Income From Continuing Operations
Add'l Income/Expense Items 8 105
Earnings Before Interest and Tax (855) (3,450)
Interest Expense 441 360
Earnings Before Tax (1,296) (3,811)
Income Tax - -
Minority Interest - -
Equity Earnings Unconsolidated Subsidiary - -
Net Income Cont. Operations (1,297) (3,811)
Non Recurring Events
Discontinued Operations - -
Extraordinary Items - -
Effect of Accounting Changes - -
Other Items - -
Net Income (1,296) (3,811)
Preferred Stock and Other Adjustments - -
Net Income Applicable to Common Shareholders (1,296) (3,811)
RegenoCell Therapeutics, Inc.
Period Ending Dec 31, 2011 Dec 31, 2010
Total Revenue 865 910
Cost of Revenue 127 92
Gross Profit 738 818
Operating Expenses
Research and Development - -
Sales, General and Admin. 1,537 1,573
Non-Recurring Items - 2,741
Other 64 59
Operating Income (863) (3,555)
Income From Continuing Operations
Add'l Income/Expense Items 8 105
Earnings Before Interest and Tax (855) (3,450)
Interest Expense 441 360
Earnings Before Tax (1,296) (3,811)
Income Tax - -
Minority Interest - -
Equity Earnings Unconsolidated Subsidiary - -
Net Income Cont. Operations (1,297) (3,811)
Non Recurring Events
Discontinued Operations - -
Extraordinary Items - -
Effect of Accounting Changes - -
Other Items - -
Net Income (1,296) (3,811)
Preferred Stock and Other Adjustments - -
Net Income Applicable to Common Shareholders (1,296) (3,811)
(0)
(0)RegenoCELL Therapeutics Inc. (RCLL) Stock Research Links
Scroll down for more posts ▼